Abstract
We have studied inhibition of Plasmodium falciparum lactate dehydrogenase (pfLDH) by dihydroxynaphthoic acid (DHNA) analogues derivatives of hemigossypol-sesquiterpene found in cottonseed known to exhibit antimalarial activity. Molecular models of pfLDH-DHNA complexes were prepared from high-resolution crystal structures containing DHNA and azole inhibitors and binding affinities of the inhibitors were computed by molecular mechanics – polarizable continuum model of solvation (MM-PCM) approach. The 3D structures of the pfLDH-DHNA complexes were validated by a QSAR model, which confirmed consistency between the computed binding affinities and experimental inhibition constants for a training set and validation set of twelve DHNA inhibitors obtained from literature. Novel more potent DHNA analogs were identified by structure-based molecular design and predicted to inhibit pfLDH in the low nanomolar concentration range. In addition, the designed DHNA analogs displayed favorable predicted ADME-related profiles and an elevated selectivity for the pfLDH over the human isoform.
Keywords: Plasmodium Falciparum, Lactate Dehydrogenase, Quantitative Structure-activity Relationships (QSAR), Molecular Modeling, Structure-based Drug Design, ADME-related Properties Prediction, Binding Specificity
Medicinal Chemistry
Title:Design of Novel Dihydroxynaphthoic Acid Inhibitors of Plasmodium Falciparum Lactate Dehydrogenase
Volume: 8 Issue: 5
Author(s): Eugene Megnassan, Melalie Keita, Cecile Bieri, Akori Esmel, Vladimir Frecer and Stanislav Miertus
Affiliation:
Keywords: Plasmodium Falciparum, Lactate Dehydrogenase, Quantitative Structure-activity Relationships (QSAR), Molecular Modeling, Structure-based Drug Design, ADME-related Properties Prediction, Binding Specificity
Abstract: We have studied inhibition of Plasmodium falciparum lactate dehydrogenase (pfLDH) by dihydroxynaphthoic acid (DHNA) analogues derivatives of hemigossypol-sesquiterpene found in cottonseed known to exhibit antimalarial activity. Molecular models of pfLDH-DHNA complexes were prepared from high-resolution crystal structures containing DHNA and azole inhibitors and binding affinities of the inhibitors were computed by molecular mechanics – polarizable continuum model of solvation (MM-PCM) approach. The 3D structures of the pfLDH-DHNA complexes were validated by a QSAR model, which confirmed consistency between the computed binding affinities and experimental inhibition constants for a training set and validation set of twelve DHNA inhibitors obtained from literature. Novel more potent DHNA analogs were identified by structure-based molecular design and predicted to inhibit pfLDH in the low nanomolar concentration range. In addition, the designed DHNA analogs displayed favorable predicted ADME-related profiles and an elevated selectivity for the pfLDH over the human isoform.
Export Options
About this article
Cite this article as:
Megnassan Eugene, Keita Melalie, Bieri Cecile, Esmel Akori, Frecer Vladimir and Miertus Stanislav, Design of Novel Dihydroxynaphthoic Acid Inhibitors of Plasmodium Falciparum Lactate Dehydrogenase, Medicinal Chemistry 2012; 8 (5) . https://dx.doi.org/10.2174/157340612802084324
DOI https://dx.doi.org/10.2174/157340612802084324 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Advances of Metal Enhanced Fluorescence Applications for the Biomedical Field
Current Proteomics Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs as Regulators in Normal Hematopoietic and Leukemia Stem Cells: Current Concepts and Clinical Implications
Current Molecular Medicine Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Patent Selections:
Current Biomarkers (Discontinued) The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Isothiocyanates as Cancer Chemopreventive Agents: Their Biological Activities and Metabolism in Rodents and Humans
Current Drug Metabolism Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Pain and Child: A Translational Hypothesis on the Pathophysiology of a Mild Type-2 Diabetes Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
Mini-Reviews in Medicinal Chemistry Proteomic Identification of a Monoclonal Antibody Recognizing Caveolin-1 in Hepatocellular Carcinoma with Metastatic Potential
Protein & Peptide Letters Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy DNA-drug Conjugates for Site-specific Delivery in Anti-cancer Therapy
Current Pharmacogenomics and Personalized Medicine Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer
Current Cancer Therapy Reviews Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology